Multiwarhead Aptamer Covalent Binding SARS-CoV-2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid aptamers have limitations in their ability to form covalent bonds with target proteins, particularly the SARS-COV-2 spike protein, which can lead to reduced efficacy in inhibiting viral infection, and there is a lack of understanding on the feasibility and effects of introducing multiple covalent-binding warheads to aptamers.
Innovation Solution
Development of multiwarhead nucleic acid aptamers with multiple fluorosulfonyl groups linked via linkers, specifically through azide-alkyne click chemistry, allowing for covalent binding to the SARS-COV-2 spike protein, enhancing binding efficiency and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nucleic acid aptamers are used, then the structure is simple and easy to manufacture, but the covalent binding ability to target proteins is limited
Solution Approach 1:
The aptamer is divided into multiple functional segments: a binding region for target recognition and multiple warhead regions (fluorosulfonyl groups) for covalent bonding. This segmentation allows the aptamer to perform both recognition and covalent attachment functions simultaneously, resolving the contradiction between binding ability and structural simplicity
Solution Approach 2:
The invention creates a composite structure by combining nucleic acid aptamer backbone with multiple fluorosulfonyl warhead groups. This composite design integrates the specificity of nucleic acid binding with the covalent reactivity of fluorosulfonyl groups, enhancing reliability while maintaining manageable complexity through modular design
2Productivity
If multiple fluorosulfonyl groups are introduced to enhance covalent binding, then binding efficiency improves, but the manufacturing complexity increases
Solution Approach 1:
The fluorosulfonyl groups are pre-installed on the aptamer structure during synthesis preparation. This preliminary action ensures that multiple warhead groups are correctly positioned before the aptamer engages with the target, maximizing binding efficiency while streamlining the manufacturing process by avoiding complex post-synthesis modifications
Solution Approach 2:
The invention optimizes parameters including the number of fluorosulfonyl groups (typically 2-5), their spacing (at least 3 residues apart), and linker lengths to achieve optimal binding efficiency. These parameter adjustments are made during synthesis design, balancing productivity enhancement with manufacturing feasibility
3Measurement precision
If multiple warheads are used to form multiple covalent bonds, then target specificity increases, but the device complexity increases
Solution Approach 1:
Different regions of the aptamer are assigned specialized functions: the binding region provides target recognition specificity while the warhead regions provide covalent attachment capability. This local quality differentiation enhances target specificity through multi-point attachment without requiring uniform complexity throughout the entire structure
Solution Approach 2:
Linker molecules serve as intermediaries between the nucleic acid backbone and the fluorosulfonyl warhead groups. These linkers facilitate proper spatial arrangement and orientation of warheads relative to the target protein, enhancing binding specificity while simplifying the overall design by providing a standardized connection module
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multiwarhead aptamers demonstrate improved covalent binding rates and target specificity, capable of forming multiple bonds with the SARS-COV-2 spike protein, significantly inhibiting viral receptor binding and infection, with enhanced pharmacological effects compared to conventional aptamers.
Implementation Method 1
wherein the reactive group is an azide group or an alkyne group, and the other reactive group is a group having a carbon-carbon triple bond or an azide group, respectively, and the linking moiety is a moiety formed by a click chemistry reaction between the reactive group and the other reactive group
Data Source
AI summary
The invention imparts new properties to nucleic acid aptamers, which may enhance its function as therapeutic drugs or the like. Also provided is a covalent drug having the new properties as an anti-SARS-COV-2 drug. Specifically, an aptamer-based multiwarhead covalent drug having multiple covalent binding warheads is provided. In particular, an aptamer-based multiwarhead covalent drug targeting SARS-COV-2 is provided. A pharmaceutical composition comprising the multiwarhead nucleic acid aptamer and a method of producing the multiwarhead nucleic acid aptamer are also provided.